☰

Empresas y finanzas

Response Genetics, Inc. Announces the Appointment of David Gandara, M.D. to Its Board of Directors


    Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the

    development of molecular diagnostic tests for cancer, announced today

    the appointment of David Gandara, M.D. to its Board of Directors. Dr.

    Gandara, a well-known expert in lung cancer and developmental

    therapeutics, brings significant medical and clinical development

    expertise in oncology to Response Genetics. He is currently a Professor

    of Medicine at the University of California, Davis School of Medicine.

    He is also the Director of Clinical Research, and the Director of the

    Thoracic Oncology Program at the U.C. Davis Cancer Center.
    Dr. Gandara brings more than 30 years of clinical and medical experience

    to Response Genetics. He is a member of the Board of Directors of the

    International Association for the Study of Lung Cancer and the Addario

    Foundation. He served as a member of the Board of Directors of the

    American Society of Clinical Oncology (ASCO) and as secretary-treasurer.

    Dr. Gandara is also a member of many professional committees, including

    the NCI Investigational Drug Steering Committee and the NCI Science

    Correlates Committee. He currently is the Chair of the Southwest

    Oncology Group´s Lung Committee (SWOG). In

    addition, Dr. Gandara is also an accomplished author who has published

    more than 225 articles, written 10 book chapters, and authored more than

    255 abstracts and 125 presentations.
    "Response Genetics is honored to welcome Dr.

    Gandara to our Board of Directors," said

    Kathleen Danenberg, CEO and President of Response Genetics, Inc. "We

    believe Dr. Gandara´s experience and expertise

    in oncology and developmental therapeutics will add considerable depth

    to our Board. We are confident that Dr. Gandara will provide invaluable

    guidance as we work aggressively to execute our business goals."
    "I am excited to join Response Genetics and

    welcome the opportunity to contribute to the company´s

    growth and to help advance the company´s

    products," commented Dr. Gandara. "I

    believe the company´s diagnostic cancer

    products have the potential to significantly improve outcomes in

    individuals with cancer."
    Dr. Gandara holds a B.A. from the University of Texas and an M.D. with

    honors from the University of Texas Medical Branch in Galveston, TX.
    About Response Genetics, Inc.
    Response Genetics, Inc. ("RGI") (the "Company")

    (NASDAQ: RGDX) is engaged in the research and development of

    pharmacogenomic cancer diagnostic tests based on its proprietary and

    patented technologies. RGI´s technologies enable extraction and analysis

    of genetic information from genes derived from tumor samples stored as

    formalin-fixed and paraffin embedded specimens. RGI currently generates

    revenue primarily from the sales of its proprietary analytical

    pharmacogenomic testing services of clinical trial specimens to the

    pharmaceutical industry. The Company was founded in 1999 and its

    principal headquarters are located in Los Angeles, California. For more

    information, please visit www.responsegenetics.com.
    Forward Looking Statement Notice
    Except for the historical information contained herein, this press

    release and the statements of representatives of RGI related thereto

    contain or may contain, among other things, certain forward-looking

    statements, within the meaning of the Private Securities Litigation

    Reform Act of 1995.
    Such forward-looking statements involve significant risks and

    uncertainties. Such statements may include, without limitation

    statements with respect to the Company´s plans, objectives, projections

    expectations and intentions, such as the ability of the Company to

    analyze cancer samples, the potential for using the results of this

    research to develop diagnostic tests for cancer, the usefulness of

    genetic information to tailor treatment to patients, the ability of the

    Company to make its ResponseDx:Lung? and

    ResponseDX:Colon? tests available in a number

    of institutions, and other statements identified by words such as

    "projects," "may," "could," "would," "should," "believes," "expects,"

    "anticipates," "estimates," "intends," "plans" or similar expressions.
    These statements are based upon the current beliefs and expectations of

    the Company´s management and are subject to significant risks and

    uncertainties, including those detailed in the Company´s filings with

    the Securities and Exchange Commission. Actual results, including

    without limitation, actual sales results, if any, or the application of

    funds, may differ from those set forth in the forward-looking

    statements. These forward-looking statements involve certain risks and

    uncertainties that are subject to change based on various factors (many

    of which are beyond the Company´s control). The Company undertakes no

    obligation to publicly update forward-looking statements, whether

    because of new information, future events or otherwise, except as

    required by law.